(Q34336876)

1 August 2017

1 reference

title

Newer antiepileptic drugs: advantages and disadvantages (English)

1 reference

1 August 2017

Wallace SJ

1

1 reference

1 August 2017

1 August 2001

1 reference

1 August 2017

Brain and Development

1 reference

1 August 2017

23

1 reference

1 August 2017

5

1 reference

1 August 2017

277-283

1 reference

The new antiepileptic drugs: a systematic review of their efficacy and tolerability

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Efficacy and tolerability of vigabatrin in children with refractory partial seizures: a single-blind dose-increasing study

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Vigabatrin: a novel therapy for seizure disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigator and Peer Review Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Vigabatrin in intractable childhood epilepsy: a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Gamma-vinyl-GABA (vigabatrin) in the therapy of Lennox-Gastaut syndrome: an open study

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Severe persistent visual field constriction associated with vigabatrin

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Visual field defects associated with vigabatrin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Characteristics of a unique visual field defect attributed to vigabatrin

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Prospective, open-label, add-on study of lamotrigine in 56 children with intractable generalized epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Lamotrigine for the treatment of epilepsy in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Lamictal (lamotrigine) monotherapy for typical absence seizures in children

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Lamotrigine and Seizure Aggravation in Severe Myoclonic Epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Lamotrigine-associated rash: risk/benefit considerations in adults and children

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Lamotrigine-induced severe cutaneous adverse reactions.

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10,11 -epoxide

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

The tolerability of lamotrigine in children

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study. Gabapentin Paediatric Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77.

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Gabapentin toxicity in children manifesting as behavioral changes.

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Behavioral side effects of gabapentin in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Effectiveness, tolerability, and safety of topiramate in children with partial-onset seizures. Topiramate YP Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Long-term response to topiramate in patients with West syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

1 reference

7 January 2021

Two cases of nonconvulsive status epilepticus in association with tiagabine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Frontal nonconvulsive status epilepticus associated with high-dose tiagabine therapy in a child with familial bilateral perisylvian polymicrogyria

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Felbamate: a clinical trial for complex partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Felbamate monotherapy: controlled trial in patients with partial onset seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome).

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

The use of felbamate to treat infantile spasms

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

1 reference

7 January 2021

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

1 reference

7 January 2021

Oxcarbazepine in the treatment of early childhood epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Stiripentol in atypical absence seizures in children: an open trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Adjustment of carbamazepine dose to offset the effects of the interaction with remacemide hydrochloride in a double-blind, multicentre, add-on drug trial (CR2237) in refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

1 reference

7 January 2021

Zonisamide-induced behavior disorder in two children.

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0387-7604%2801%2900230-3

7 January 2021

10.1016/S0387-7604(01)00230-3

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

11504596